Concr, a London-based techbio company, applies astrophysics methods to predict cancer treatment outcomes. Their platform, FarrSight®, enables accurate tumor modeling and clinical trial simulations, revolutionizing therapy prediction without relying on extensive data. With investors like University of Cambridge Enterprise and Oncology Ventures, Concr aims to reshape cancer treatment paradigms globally.